No, there is no widely available cure for AIDS or HIV. A handful of individuals have been cured through extreme medical procedures, and daily medication now allows most people with HIV to live near-normal lifespans. But a safe, scalable cure that could work for the roughly 39 million people living with HIV worldwide does not yet exist.
That said, the science has moved dramatically. What was a death sentence in the 1980s is now a manageable chronic condition, and several experimental approaches are inching closer to making a true cure possible.
The People Who Have Been Cured
A small number of people have achieved what scientists call a “sterilizing cure,” meaning no detectable HIV remains in their bodies. The most famous is Timothy Ray Brown, known as the Berlin Patient, who in 2007 received two bone marrow transplants to treat his leukemia. The donor carried a rare genetic mutation that prevents a protein called CCR5 from appearing on the surface of immune cells. HIV uses CCR5 as a doorway to infect cells, so without it, the virus has no way in. After the transplants, Brown’s HIV never came back.
A second person, known as the London Patient, achieved the same result years later using a single transplant from a donor with the same mutation, this time to treat Hodgkin lymphoma. Several more cases have followed the same pattern. The common thread in all of them: the person already had a life-threatening cancer that justified the transplant, and a matching donor with that rare CCR5 mutation was available.
Why That Cure Can’t Be Used for Everyone
Bone marrow transplants are among the most dangerous procedures in medicine. In one review of 30 HIV-positive patients who received transplants between 1987 and 2003, treatment-related mortality was 46% at 100 days and 68% at two years. Deaths were caused by lung toxicity, infections, and HIV disease itself. The procedure also requires finding a genetically matched donor who carries the CCR5 mutation, which occurs naturally in only about 1% of people of European descent and is far rarer in other populations.
No doctor would recommend a procedure with that level of risk to someone whose HIV is already well controlled by medication. These cases proved that eliminating HIV from the body is biologically possible, but they represent a therapeutic exception, not a path to a general cure.
Why HIV Is So Hard to Eliminate
The core problem is something called the latent reservoir. When HIV infects the body, it inserts its genetic code into certain long-lived immune cells (resting memory CD4+ T cells) and goes dormant. These sleeping infected cells produce almost no viral proteins, which makes them invisible to both the immune system and antiviral drugs. They can persist in this quiet state for years, with a half-life of roughly six months per cell generation.
The reservoir doesn’t shrink significantly over time, even with decades of treatment. But the moment medication stops, those dormant cells can wake up, start producing new virus, and reignite the infection. This is why people who stop taking their medication almost always see their viral levels rebound. It’s also why current drugs, as effective as they are, cannot finish the job on their own.
How Treatment Has Changed the Outlook
Modern antiretroviral therapy has transformed HIV from a fatal diagnosis into something closer to a chronic condition like diabetes. People who start treatment early and take it consistently can suppress the virus to undetectable levels, which also means they cannot transmit it to sexual partners.
Life expectancy for people on treatment now ranges from about 60% to 89% of the general population’s, depending on the country. In Canada, a 20-year-old starting treatment can expect to live roughly 89% as long as someone without HIV. In lower-resource settings like Rwanda, that figure drops to about 60%, largely due to later diagnosis, differences in healthcare access, and other health challenges. The gap continues to narrow as treatment improves, but it hasn’t fully closed yet.
Experimental Strategies Being Tested
Scientists are pursuing several fundamentally different approaches to a cure, each targeting the latent reservoir problem from a different angle.
Shock and Kill
This strategy tries to wake up dormant infected cells using drugs called latency-reversing agents, forcing them to reveal themselves. Once active, the cells would theoretically be destroyed by the immune system or the virus itself. Early clinical trials showed these agents could activate viral RNA in sleeping cells, but they failed to actually shrink the reservoir. The “kill” step, it turns out, needs significant improvement.
Block and Lock
The opposite approach: instead of flushing the virus out, lock it into permanent silence. If every dormant copy of HIV could be prevented from ever reactivating, a person could stop medication without the virus rebounding. One compound has shown promise in mouse models, delaying viral rebound after treatment was stopped. This strategy wouldn’t eliminate HIV from the body but could achieve what researchers call a “functional cure,” similar to cancer remission, where the virus is present but permanently inactive.
Gene Editing With CRISPR
Perhaps the most ambitious approach uses CRISPR gene-editing technology to cut HIV’s genetic code directly out of infected cells. A therapy called EBT-101 became the first CRISPR-based HIV treatment tested in humans, delivered via a viral vector to six participants with suppressed viral loads. The treatment was safe and well tolerated, but when three participants stopped their medication, all three saw their virus return. A single dose wasn’t enough to eliminate the reservoir. Researchers are now working to improve the therapy’s reach and potency.
The Role of Elite Controllers
About 1 in 300 people with HIV can suppress the virus to undetectable levels without any medication at all. These “elite controllers” have become a major focus of cure research because their bodies do naturally what scientists are trying to achieve artificially. Studies have linked this ability partly to specific variations in immune system genes that allow their killer T cells to recognize and destroy HIV-infected cells more effectively. However, genetics explain less than 25% of the difference between controllers and other people with HIV, meaning other factors are still being identified.
Understanding what makes elite controllers different could eventually lead to therapies, like therapeutic vaccines or immune-boosting treatments, that mimic their natural advantage in everyone else.
Vaccines: Prevention and Treatment
After decades of failed attempts, HIV vaccine research has entered a new phase. The International AIDS Vaccine Initiative launched a Phase 1 trial called IAVI G004, testing three HIV-targeting proteins delivered on Moderna’s mRNA platform in 96 participants across six sites in South Africa. This approach uses a strategy called “germline targeting,” which aims to train the immune system step by step to produce broadly neutralizing antibodies, the kind that can block many different strains of HIV. It’s still early-stage work, but the mRNA platform that proved successful during COVID-19 has given the field new tools and momentum.
A preventive vaccine would not cure people already living with HIV, but a therapeutic vaccine, one that teaches an already-infected person’s immune system to control the virus without drugs, could function as a practical cure for millions.
Where Things Stand Globally
The United Nations has set a goal of ending AIDS as a public health threat by 2030, defined as reducing new infections and AIDS-related deaths by 90% compared to 2010 levels. Progress has been real but uneven. Treatment access has expanded enormously, but new infections have not declined fast enough, particularly in sub-Saharan Africa, among adolescent girls and young women, and in marginalized communities with less access to healthcare.
The honest answer to “did they find a cure for AIDS” is: not yet, but the science is closer than it has ever been. For now, the practical reality is that consistent treatment lets most people with HIV live long, healthy lives, and multiple experimental approaches are working toward making medication optional. A safe, affordable, widely available cure remains the goal, and for the first time in the epidemic’s history, it looks like a realistic one.